medigraphic.com
ISSN 0210-5187 (Electronic)

2005, Number 6

<< Back Next >>

Med Cutan Iber Lat Am 2005; 33 (6)

Leishmaniasis and AIDS

Goreti BM

Language: Spanish
References: 77
Page: 237-250
PDF size: 429.69 Kb.


ABSTRACT

Leishmaniasis is a parasitic infection caused by a protozoa belonging to the genus “Leishmania”. The disease is endemic in the tropical countries as well in the Mediterranean basin. During the last 10 years, with the advent of human immunodeficiency virus infection (HIV), the number of cases of visceral leishmaniasis has dramatically increased, mainly in Spain, Italy, France and Portugal, as a result of its overlapping with AIDS. Moreover, this «co-infection “Leishmania”/HIV» has been responsible for unknown clinical manifestations of the disease and for frequent parasited cutaneous lesions with “Leishmania” in these patients. Impaired immune system leads also to a loss of the common relationship between species and clinical presentation. We present a revision of the literature and some personal cases of such modifications in the clinics of cutaneous leishmaniasis related to HIV infection.


REFERENCES

  1. Grevelink SA, Lerner E. Leishmaniasis. J Am Acad Dermatol 1996;34:257-72.

  2. Choi C, Lerner E. Leishmaniasis. J Inv Dermatol Symp Proc 2001;6:175-82.

  3. Heewaldt BL. Leishmaniasis. Lancet 1999;354:1191-99.

  4. Rosenthal E, Marty P, Guidice P, et al. HIV/AIDS Brief reports. HIV and Leishmania coinfection: a review of 91 cases with focus on atypical locations of Leishmania. Clin Inf Dis 2000;31:1093-5.

  5. Alvar J, Cañavate C, Gutiérrez-solar B, Jiménez M, e tal. Leishmania and human immnunodeficiency vírus coinfection: the first 10 years. Clin Microb Rev 1997;10: 298-319.

  6. Puig L, Pradinaud R. HIV/Leishmania coinfections: dermatological manifestations. Ann Trop Med Parasitol 2002;97:S107-S14.

  7. Marty P, Ozon C, Rahal A, et al. Leishmaniose dans les Alpes-Maritimes. Caractéristiques épidémiologiques actuelles. Méd et Arm, 1994;22:29-31.

  8. Campino L. Leishmanioses em Portugal. Características emergentes da epidemiologia e do diagnóstico. Tese. 1998;Lisboa,pp.3-158.

  9. Vabres P, Marty P, et al. Leishmaniose cutanée autochtone due à Leishmania infantum confirmés par immunoempreinte. Ann Dermatol Venereol 2001;128:1047-50.

  10. Campino L, Abranches. Leishmaniose cutânea. Uma doença rara em Portugal? Acta Méd Portugu 2002;15:387-90.

  11. Desjeux P, Alvar J. Leishmania/HIV coinfections: epidemiology in Europe. Ann Trop Med Parasitol 2003;97:Supp1:S3-S15.

  12. World Wealth Organization. Leishmania/HIV co-infection. South-western Europe 1990-1998.Document WHO/LEISH/ 2000.42,Geneve,WHO,2000.

  13. Dedet JP et Pratlong F. Leishmaniasis. Manson’s tropical diseases. Cook GCJ Zumba A Eds WB Saunders, 21st ed, 2003,London, p.1339- 64.

  14. Molina R, Gradoni L, Alvar J. HIV and the transmission of Leishmania. Ann Trop Med Parasitol 2003;97:Supp 1:S29-S45.

  15. Rabello A, Orsini M, Disch J. Leishmania/HIVco-infection in Brazil: an appraisal. Ann Trop Med Parasitol 2003;97:Supp 1:S17-S28.

  16. Wolday D, Berhe N, Akuffo H, Britton S. Leishmania-HIV interaction: immunopathogenic mechanisms. Parasitol Today 15:182-186,1999.

  17. Desjeux P. Global control and Leishmania HIV co-infection. Clin Dermatol 1999;17: 317-25.

  18. Desjeux P. Leishmania HIV co-infection: the European experience. World health Organization (WHO), Geneve, 2004.

  19. Darie H. Dermatologie du voyageur Ann Dermatol Venereol 2002; 129:1183-90.

  20. Pratlong F, Dereure J, Deniau M, Marty P, Faraut-Gambarelli F, Dedet JP. Enzymatic polymorphism during Leishmania/HIV co-infection: a study of 381 Leishmania strains received between 1986 and 2000 at the international cryobank in Montpellier, France. Ann Trop Med Parasitol 2002;97: S47-S56.

  21. Giudice P, Marty P, Lacour JP, Perrin C, Pratlong F, Haas H, Dellamonica P, Le Fichoux Y. Cutâneous leishmaniasis due two to Leishmania infantum. Case reports and literature review. Arch Dermatol 1998;134: 193-198.

  22. Pratlong F, Dereure J, et al. Sudan: the possible original focus of visceral leishmaniasis. Parasitol 2001;122:599:05.

  23. Dedet JP, Pratlong F. Taxonomie des Leishmania et distribuition géographique des leishmanioses. Ann Dermatol Venereol 2000;127:421-24.

  24. Campino L, Santos- Gomes G, et al. The isolation of Leishmania donovani MON-18, from an AIDS patient in Portugal: possible needle transmission. Parasite 1994;1:391-92.

  25. Kharfi M, Fazaa B, et al. Localisation muqueuse de la leishmaniose en Tunisie: 5 observations. Ann Dermatol Venereol 2003; 130: 27-30.

  26. Mattos M, Caiza A, et al. American cutaneous leishmaniasis associated with HIV infection: report of four cases. JEAD 1998; 10:218-25.

  27. Souza IS, Naiff RD, et al. American cutaneous leishmaniasis due to Leishmania (Viannia) guyanensis as an initial clinical presentation of human immunodeficiency virus infection. JEADV 1998;10:214-17.

  28. D’Alessandro-Bacigalupo Protozoários flagelados (Mastigophora). In Faust EC, Beaver PC, Jung RC. Agentes e vectores animais de doenças humanas, 4ª ed, Lisboa, Fundação Calouste Gulbenkian, 1975, 35-82

  29. Rosatelli JB, Souza CS, et al. Generalized cutaneous leishmaniasis in acquired immunodeficiency syndrome. JEADV 1998; 10:229-32.

  30. Durand I, Beylot-Barry M, et al. Leishmaniose cutanée diffuse révélatrice d’une infection par le virus de l’immunodéficience humaine. Ann Dermat Venereol 1998; 125:268-70.

  31. Mahé A, Bobin P, et al. Dermatoses révélatrices de l’infection par le virus de l’immunodéficience humaine au Mali. Ann Dermat Venereol 1997:144-50.

  32. Grüber SC, Rangel OZ, Lugo AR. Leishmaniasis en la infancia. Med Cut Iber Lat Am 2003;31:351-61.

  33. Russo R, Laguna F, López-Véléz R, Medrano FJ, et al. Visceral leishmaniasis in those infected with HIV: clinical aspects and other opportunistic infections. Ann Trop Med Parasit 2003;97:S99-S105.

  34. Russo R, Nigro L, Panarello G, et al. Clinical survey of Leishmania HIV co- infection in Catania, Italy: the impact of highly active antiretroviral therapy (HAART). Ann Trop Med Parasit 2003;97:S149-S55.

  35. Magili A, Grögl M, Grasser R, et al. Visceral infection caused by Leishmania tropica in veterans of operation desert storm. N Eng J Med, 1993;328:1383-87.

  36. Colebunders R, Depraetere K, Verstraeten T, Lambert J, Hauben E, Van Marck E, et al. Unusual cutaneous lesions in two patients with visceral leishmaniasis and HIV infection. J Am Acad Dermatol 1999;41:847-50.

  37. Herrera E, Bosh RJ, et al. The presence and significance of Leishmania in mucocutaneous biopsies from HIV+ patients with visceral leishmaniasis. E J Dermatol 1996; 6:501-4.

  38. Perrin C, Taillan B, et al. Aypical cutaneous histological features of visceral leishmaniasis in acquired immunodeficiency syndrome. Am J Dermatop 1995;17:145-50.

  39. Kligman AM. The invisible dermatoses. Arch Dermatol 1991;127:1375-82.

  40. Ara M, Maillo C, et al. Visceral leishmaniasis with cutaneous lesions in a patient infected with human immunodeficiency virus. Br J Dermatol 1998;139:114-17.

  41. Guidice P. Leishmania infection occurring in herpes zoster lesions in an HIV patient. Br J Dermat 1996;135:1003-17.

  42. Barrio J, Lecona M, et al. Leishmania infection occurring in herpes zoster lesions in a HIV-positive patient. Br J Dermatol 1996;134:164-66.

  43. Yebra M, Segovia J, Manzano L, Vargas JA, Bernaldo de Quiros L, et al. Disseminated-to-skin kala-azar and the acquired immunodeficiency syndrome. Ann Int Med 1988;108:490-91

  44. Campino L, Santos-Gomes GM, Pratlong F, AntunesF, Mauricio I, Dedet JP, et al. HIV/Leishmania co-infections in Portugal: diagnosis and isoenzyme characterization of Leishmania. Ann Trop Med Parasit 1997; 91:433-36.

  45. Postigo C, Llamas R, Zarco C, Rubio R, Pulido F, Costa JR, et al. Cutaneous lesions in patients with visceral leishmaniasis and HIV infection. J Infect 1997;35:265-8.

  46. E Dauden, P F Penas, L Rios, M Jimenez, J Fraga, J Alvar, A Garcia-Diez. Leishmaniasis presenting as a dermatomyositis-like eruption in AIDS. J Am Acad Der; 1996;35:316-9.

  47. Foryth SF, Lawn SD, Miller RF, et al. Multiple dermatofibroma-like lesions in a human immunodeficiency virus-positive patient coinfected with visceral leishmaniasis. Br J Dermatolo 2003;148:185-6

  48. González-Beato MJ, Moyano B, et al. Kaposi’s sarcoma-like lesions and other nodules as cutaneous involvement in AIDSrelated visceral leishmaniasis. Br J Dermatol Br J Derm 2000;143:1316-18.

  49. Marques S, Aldomiro F, Pacheco M, et al. Simultaneous visceral and cutaneous leishmaniasis in HIV infected patients. XIV International AIDS Conference. Barcelona, Spain, July 7-12,2003.

  50. Zijlstra AE, Musa AM, Khalil EAG, el-Hassan IM, el-Hassan AM. Post-kala-azar dermal leishmaniasis. Lancet Inf Diseas 2003;3:87-98.

  51. Roustan G, Jiménez JA, Gutiérrez-Solar B, et al. Post-kala-azar dermal leishmaniasis with mucosal involvement in a kidney transplant recipient: treatamnet with liposomal amphotericin B. Br J Dermat 1998; 138: 526-28.

  52. Ridolfo AL, Gervasoni C, Antinori S, Pizzuto M, Santambrogio S, Trabattoni D, et al. Post-kala-azar dermal leishmaniasis during highly active antiretroviral therapy in an AIDS patient infected with Leishmania infantum. J Infect 2000;40:199-202.

  53. Catorze G, Alberto J, Afonso A, et al. Co-infection Leishmania infantum /VIH: lésions cutanées après le traitement de la leishmaniose viscérale. Ann Dermat Venereol (no prelo).

  54. Calza L, D’Antuono, Marinacci G, et al. Disseminated cutaneous leishmaniasis after visceral disease in a patient with AIDS. J Am Acad Dermatol 2004;50:461-5.

  55. Deniau M, Cañavate C, Faraut F, et al. The biological diagnosis of leishmaniasis in HIVinfected patients. Ann Trop Med Parasit 2003;97,Sup1:S115-S33.

  56. Weedon David. Protozoal infections. In David Weedon Skin pathology, 2nd edition, Churchill Livingstone, 719-725, 2002.

  57. Catorze G. Leishmanioses. Trab Soc Port Dermatol Venereol 2003;61:273-97.

  58. Cortes S, Rolao N, Ramada J, Campino L. PCR as a rapid and sensitive tool in the diagnosis of human and canine leishmaniasis using Leishmania donovani s.l.-specific kinetoplastid primers. Trans R Soc Trop Med Hyg 2004;98:12-7.

  59. Bosolasco S, Gaiera G, Olchini D, et al. Real-Time PCR assay for clinical management of human immunodeficiency virus-infected patients with visceral leishmaniasis. J Clin Microbiol 2003;41:5080-4.

  60. Campino L, Cortes, et al. Detection of leishmania in immunocompromised patients using periferal blood spots on filter paper and the polymerase chain reaction. Eur J Clin Microbiol Infect Dis 2000;19:396-8.

  61. Campino L, Santos-Gomes GM, et al. HIV/Leishmania co-infections in Portugal: diagnosis and isoenzyme characterization of Leishmania. Ann Trop Med Parasit 1997; 91:433-36.

  62. Chicharro C, Jiménez MI, Alvar J. Isoenzymatic variability of Leishmania infantum in Spain. Ann Trop Med Parasit 2003;97:S57-S64.

  63. Gramiccia M. The identification and variability of the parasites causing leishmaniasis in HIV-positive patients in Italy. Ann Trop Med Parasit 2003, 97(1), S65-S73.

  64. Santos-Gomes G, Gomes-Pereira S, et al. Performance of immunoblotting in diagnosis of visceral leishmaniasis in human immunodeficiency virus-Leishmania sp.- Coinfected patients. J Clin Microb 2000;38:175-8.

  65. Olivier M, Badaró R, Medrano FJ, et al. The pathogenesis of Leishmania/HIV coinfection: cellular and immunological mechanisms. Ann Trop Med Parasit 2003; 97, Sup 1, S79-S98.

  66. Berman JD. Human Leishmaniasis: clinical, diagnostic, and chemotherapeutic developments in the last 10 years. Clin infect dis 1997;24:684-703.

  67. Freire M, Badaró F, et al. Efficacy and tolerability of liposomal amphotericin B (Ambisome) in the treatment of visceral leishmaniasis in Brazil The Braz J Inf Dis 1997;1:230-40.

  68. Sundar S, Jha TK,et al. Oral miltefosina for Indian visceral leishmaniasis. N Eng J Med. 2002;22:1739-46.

  69. Jacobs S. An oral drug for Leishamniasis. N Eng J Med 347:1737-38

  70. Burton A. Miltefosine-oral victory over visceral leishmaniasis. Lancet 2003;3:64.

  71. Soto J, Toledo J, Soto P, Berman J. Las alternativas terapeuticas em leishmaniasis. CILAD, I Simposio Internacional de Dermatologia Infecciosa. Valencia, 1-4 diciembre 2004.

  72. Duarte C, Candeias N, Flora L,et al. Visceral leishmaniasis and HIV infection. 2nd IAS Conference on HIV Pathogenesis and treatment. Paris,13-16July2003.

  73. Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasit 2003;97:S135-S42.

  74. López-Vélez R. The impact of highly active antiretroviral therapy (HAART) on visceral leishmaniasis in Spanish patients who are co-infected with HIV. Ann Trop Med Parasit. 2003;97:S143-S7.

  75. Nierengarten MB. Field trial of a vaccine against New World cutaneous leishmaniasis in an at-risk child population: how long does protection last? J Inf Dis 2003;187:1959-61.

  76. Iborra S, Sotto M, Carrion J, et al. Vaccination with a plasmid DNA cocktail encoding the nucleosomal histones of Leishmania confers protection against murine cutaneous leishmaniosis. Vaccine 2004;22:3865-76.

  77. Jashin J, Huang D, Pang K, et al. Vaccines and immunotherapies for the prevention of infectious diseases having cutaneous manifestations. J Am Acad Dermatol 2004;50:495-528.




2020     |     www.medigraphic.com